Renowned Speakers
Timothy Miller
Washington University School of Medicine in St. Louis USA
Kalliopi Megari
Aristotle University of Thessaloniki Greece
Sybille Krauss
Deutsches Zentrum Neurodegenerative Erkrankungen, Germany
Jun Liu
Sun Yat-sen University China
Henne Holstege
Amsterdam UMC Netherlands
Ana Beato
University Lusófona, Portugal
Maged El Setouhy
Ain Shams University Egypt
Ahmed M Al-Ansari
Arabian Gulf University, Bahrain
Recommended Global Neuroscience Webinars & Conferences
Asia Pacific & Middle East
Alzheimers-2025
About Conference
We are pleased to extend an invitation to you to attend the “The 15th Global Alzheimer's Summit “(Alzheimer 2025), which will take place in Paris, France's beautiful city. Held on June 23-24, 2025, this event offers a special experience, enabling global collaboration under the theme " Global Unity in Alzheimer's: Together for a Cure " through both in-person and virtual participation.
This conference also offers a unique opportunity to engage with leading experts, researchers, and healthcare professionals in the field of Alzheimer's disease. This summit provides a platform for sharing the latest advancements in research, treatment, and care strategies, fostering collaboration across disciplines. Attendees will gain valuable insights into innovative approaches to Alzheimer’s prevention, diagnosis, and therapy. The event also offers networking opportunities with global thought leaders, enhancing professional growth and contributing to the collective effort in addressing this critical public health challenge.
Why to attend?
1. Cutting-Edge Research and Innovations
- Gain insights into the latest advancements in Alzheimer’s research, including new therapeutic approaches, diagnostic tools, and care strategies. This summit is a platform where groundbreaking studies are presented, offering you a chance to stay at the forefront of the field.
2. Networking Opportunities
- Connect with a global network of professionals, including neurologists, psychiatrists, researchers, and healthcare providers. The summit provides a rare chance to collaborate, share ideas, and establish partnerships that can drive your work forward.
3. Expert-Led Sessions
- Learn from top experts who will share their knowledge and experience in managing and treating Alzheimer’s disease. The sessions will cover a broad range of topics, from molecular biology to patient care, ensuring a comprehensive understanding of the disease.
4. Innovative Solutions in Care
- Discover innovative approaches to improving the quality of life for patients and their caregivers. The summit will highlight successful case studies and new care models that can be implemented in various healthcare settings.
5. Global Perspectives
- Experience diverse perspectives from around the world. The summit gathers attendees from different countries, allowing you to explore global challenges and solutions in Alzheimer’s care and research.
6. Influence Future Research
- Participate in discussions that can shape the future of Alzheimer’s research and care. Your insights and experiences can contribute to the collective knowledge, helping to guide future initiatives and policies.
7. Explore Paris
- Lastly, the summit takes place in Paris, a city known for its rich history, culture, and beauty. Attending the conference also provides an opportunity to explore this iconic city and experience its unique charm.
Who can attend?
1. Healthcare Professionals: Neurologists, Geriatricians, Psychiatrists, Nurses, Primary Care Physicians, Clinical Researchers and Pharmacists.
2. Researchers and Scientists: Neuroscientists, Geneticists, Epidemiologists, Biochemists and Clinical Trial Coordinators
3. Academics and Educators: University Professors, Students and Public Health Educators.
4. Policy Makers and Health Administrators: Government Officials, Health Organization Representatives and Non-Governmental Organizations (NGOs).
5. Pharmaceutical and Biotechnology Industry: Pharmaceutical Representatives, Biotech Firms, Medical Device Companies, Venture Capitalists and Investors.
6. Caregivers and Advocacy Groups: Family Caregivers, Alzheimer’s Advocates and Support Group Leaders.
7. Patients and People Living with Alzheimer's: Patients and Patient Advocacy Groups.
8. Media and Press: Health Journalists, Science Writers and Documentary Filmmakers.
9. General Public: People Interested in Alzheimer ’s disease.
Session and Track
Track 1: Advances in Alzheimer’s disease Research:
Advances in Alzheimer’s disease research are rapidly expanding our understanding of this complex condition. Recent breakthroughs include the development of new diagnostic tools that allow for earlier detection and more accurate assessment of disease progression. Researchers are also exploring novel therapeutic approaches, such as targeting amyloid-beta plaques and tau tangles, as well as investigating the role of inflammation and genetic factors. Innovative treatments, including disease-modifying drugs and immunotherapies, are showing promise in clinical trials. These advancements aim to improve patient outcomes and ultimately find a cure for Alzheimer’s disease.
Track 2:Clinical Trials and Therapeutic Approaches:
Clinical trials for Alzheimer’s disease are crucial in evaluating new therapeutic approaches designed to slow or halt disease progression. These trials often test innovative drugs that target amyloid-beta plaques, tau tangles, and other key pathological features of the disease. Additionally, researchers are exploring gene therapy, immunotherapy, and lifestyle interventions to enhance cognitive function and delay symptoms. Each trial aims to provide valuable insights into the efficacy and safety of new treatments, contributing to a broader understanding of how to effectively manage and ultimately cure Alzheimer’s disease.
Track 3: Cognitive Health and Early Detection:
Cognitive health refers to the state of mental functions such as learning, thinking, reasoning, and remembering. It’s crucial for overall well-being and daily functioning. Early detection of Alzheimer’s disease, a common form of dementia, involves identifying signs and symptoms before they significantly impact daily life. This process often includes monitoring changes in memory, problem-solving, and language abilities. Early diagnosis can lead to timely interventions, which may help manage symptoms and improve quality of life for individuals and their families. Regular cognitive assessments and awareness of risk factors can aid in detecting the disease in its early stages.
Track 4: Advances in Caregiving and Patient Support:
Advances in caregiving and patient support for Alzheimer's disease focus on improving the quality of life for both patients and their caregivers. Recent developments include:
- Innovative Therapies: New medications and non-drug treatments aim to slow disease progression and manage symptoms more effectively.
- Technology Integration: Smart home devices, wearable sensors, and mobile apps help monitor patient well-being, provide reminders, and enhance safety.
- Caregiver Support: Enhanced training programs and support networks offer caregivers strategies to manage daily challenges and reduce stress.
- Personalized Care Plans: Tailored care approaches consider individual patient needs and preferences, improving overall care and engagement.
Track 5: Alzheimer’s and Comorbidities:
Alzheimer’s disease is a progressive neurological disorder characterized by memory loss, cognitive decline, and behavioral changes. It primarily affects older adults and is the most common cause of dementia. As Alzheimer’s advances, it disrupts daily functioning and impairs the ability to perform routine tasks. Comorbidities refer to additional medical conditions that often occur alongside Alzheimer’s disease. These can include cardiovascular diseases (such as hypertension and heart disease), diabetes, and depression. The presence of these conditions can complicate the management of Alzheimer’s and may accelerate cognitive decline, affecting overall health and quality of life. Managing comorbidities effectively is crucial for improving outcomes and maintaining well-being in individuals with Alzheimer’s.
Track 6: Global Perspectives on Alzheimer’s disease:
Alzheimer's disease, a progressive neurological disorder, poses significant challenges worldwide. Its prevalence is rising due to aging populations, with varying impacts across different regions. In high-income countries, advanced healthcare systems provide early diagnosis and access to specialized care, though the cost of treatment and care remains a concern. In contrast, low- and middle-income countries often face gaps in awareness, diagnosis, and treatment, exacerbated by limited resources and healthcare infrastructure. Cultural differences also influence perceptions and management of the disease. Global initiatives are focusing on improving awareness, research, and equitable access to care to address these disparities and advance understanding of Alzheimer's on a global scale.
Track 7: Innovations in Neurotechnology:
Recent innovations in neurotechnology for Alzheimer's disease are transforming diagnosis and treatment. Advances include:
- Early Detection: New imaging techniques and biomarkers are enabling earlier and more accurate diagnosis, allowing for earlier intervention.
- Wearable Devices: Wearables are being developed to monitor cognitive function and detect changes in behavior or physical activity, which can signal disease progression.
- Neurostimulation: Techniques like transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) are being explored to modulate brain activity and potentially slow cognitive decline.
- Artificial Intelligence: AI and machine learning are being used to analyze large datasets from brain scans and genetic information to predict disease risk and tailor treatments.
- Drug Delivery Systems: Advanced drug delivery methods, including nanotechnology, are improving the precision and efficacy of treatments, targeting specific brain regions affected by Alzheimer's.
Track 8: Ethical, Legal, and Social Implications:
Alzheimer’s disease presents significant ethical, legal, and social challenges. Ethically, there are concerns about patient autonomy, especially as cognitive decline impairs decision-making capabilities. Issues include informed consent and the right to refuse treatment. Legally, guardianship and power of attorney become critical as individuals lose capacity, raising questions about the management of their affairs and protection from exploitation. Socially, Alzheimer’s affects family dynamics, caregiving responsibilities, and the stigma associated with dementia. Addressing these implications requires a balance between respecting individual rights and providing necessary care and support.
Track 9: Public Health Initiatives and Advocacy:
Public health initiatives and advocacy for Alzheimer's disease focus on raising awareness, improving education, and supporting research to combat the disease. These efforts aim to enhance early detection and diagnosis, provide support for patients and caregivers, and influence policy to allocate resources and funding for Alzheimer's research. Public health campaigns often include community outreach, educational programs, and advocacy efforts to promote understanding and reduce stigma associated with Alzheimer's disease. Additionally, partnerships between organizations, healthcare providers, and policymakers play a crucial role in advancing care and treatment options for those affected by the disease.
Track 10: Future Directions and Emerging Trends:
Future directions and emerging trends in Alzheimer's research are focused on several key areas:
- Early Detection and Diagnosis: Advances in imaging technologies, biomarkers, and genetic profiling are enhancing early detection of Alzheimer's, potentially allowing for intervention before significant cognitive decline occurs.
- Personalized Medicine: Tailoring treatments based on individual genetic and molecular profiles is becoming more feasible, offering the potential for more effective and targeted therapies.
- Disease Modifying Therapies: Researchers are exploring drugs that can alter the course of the disease rather than just alleviating symptoms. This includes targeting amyloid plaques, tau tangles, and neuroinflammation.
- Neuroplasticity and Cognitive Training: Studies are investigating how cognitive training and lifestyle interventions might enhance brain resilience and slow the progression of Alzheimer's.
- Genetic and Environmental Factors: Ongoing research is delving into how genetics and environmental factors contribute to the risk of Alzheimer's, aiming to identify new prevention strategies.
Dementia is more than one illness. It's an umbrella phrase for a group of signs and symptoms that people with a range of illnesses, including Alzheimer's disease, may encounter. Disorders categorised as "dementia" in general are brought on by aberrant alterations in the brain. A reduction in thinking abilities, or cognitive capacities, that is severe enough to affect everyday functioning and independent living is brought on by dementia symptoms. Relationships, behaviour, and emotions are also impacted. In 60–80% of cases, the cause is Alzheimer's disease. Vascular dementia, which results from cerebral blood vessel obstruction and microscopic hemorrhage, is the second most prevalent type of dementia. People with mixed dementia simultaneously exhibit alterations in their brains consistent with several different types of dementia.Other disorders, some of which are treatable, such as thyroid issues and vitamin deficiencies, can also produce signs of cognitive impairment without becoming dementia. The terms "senility" or "senile dementia," which were once widely accepted but inaccurate, are sometimes used to misidentify dementia. This is because significant mental decline is not considered a natural aspect of ageing.
The process by which information and understanding are gained through experience, thought, and the senses is known as cognition. It includes a number of high-level cognitive processes and activities, including language, visuospatial function, planning, decision-making, memory, judgement, attention, and perception. Cognitive processes create new knowledge by applying preexisting knowledge. The word "cognitive deficit" is broad and used to characterise impairments in various cognitive domains. Cognitive impairment is not specific to any one illness or condition; rather, it could be a symptom of an underlying medical issue. It's also used to mean "cognitive impairment" interchangeably. It could be a transitory state or a gradual, long-term phenomenon.
Neuroimaging is the objective, non-invasive method of scientifically investigating the healthy human brain through the use of quantitative (computational) tools to research the anatomy and function of the central nervous system. It is also being utilised more and more in quantitative research studies related to mental health and brain disorders. Neuroimaging is not a medical speciality; rather, it is a highly diverse field including computer technology, psychology, statistics, and neuroscience. Neuroradiology and neuroimaging can occasionally be mistaken. Radiologists are medical professionals that specialise in neuroradiology, a branch of medicine that uses non-statistical brain imaging in a therapeutic context. The primary goal of neuroradiology is to identify lesions of the brain, including inflammatory diseases, tumours, vascular disorders, and strokes.
The study of epidemiology focusses on the frequency and causes of disease in various populations. Planned and evaluated sickness prevention methods as well as patient management in cases where disease has already manifested are guided by epidemiological data. An essential component of a disease's basic description is its epidemiology, much like its pathology and clinical findings. The discipline has unique methods for gathering and interpreting data, as well as the specialised vocabulary required for technical phrases. The goal of this brief book is to give a basic overview of the epidemiological approach, including its vocabulary and techniques. All we'll assume is that readers are aware of the value of providing answers to epidemiological enquiries. Some of the distinguishing features of the epidemiological method will be highlighted in this introduction.
The goal of an intervention is to encourage someone to get professional help for a substance use disorder, a traumatic incident or crisis, or other major condition. Interventions can involve one or more persons, most often family and friends. The use of a comparable strategy in a therapeutic session is another term for intervention. A number of severe personal issues have been addressed through interventions, such as self-harm, abuse victimisation, compulsive gambling, substance addiction, compulsive eating and other eating disorders, and alcohol use disorder.
The central nervous system (CNS) can become inflamed due to autoimmune diseases, toxicity, injury, or infection. As the specific resident macrophage cells in the central nervous system, microglia are essential for the development and treatment of neuroinflammation. Their effect on neurones is complicated, though. The local brain microenvironment has a direct impact on the phenotypic plasticity of microglia. Therefore, the underlying variety of the microglial population is not adequately reflected by the M1/M2 dichotomy labelling that is used to describe other macrophage activity. It is well known that the expression of genes included in both M1 and M2 profiles is a component of the "disease-associated microglia signature" that microglia may exhibit in neurodegenerative diseases. Microglia thus have a role in the neuronal loss typical of these disorders, even though they are crucial for the first response to neuronal injury.
The study of neuroscience focusses on the anatomy and physiology of the human nerve system and brain. To map the brain mechanistically, neuroscientists draw on fields such as cellular and molecular biology, anatomy and physiology, human behaviour, and cognition, among others. An estimated 100 billion neurones, or brain cells, make up the human brain, each of which has roughly a thousand connections to other cells. Mapping the networks of cell-to-cell communication—the brain circuits that process all thoughts, feelings, and behaviours—is one of the major difficulties facing modern neuroscience. The resulting image, which gradually takes shape, is called "the connectome." All learning is driven by the brain's capacity for neuroplasticity, or the creation of new neural circuits and connections.
The study of neuroscience brings together biology and psychology to address issues like how the brain processes pain or what causes Parkinson's disease. Researchers and medical professionals are gaining new insights into the physical structure of the brain, its five million kilometres of wire, and its relationship to the rest of the mind and body thanks to computer simulations, imaging, and other techniques.
Memory loss is a general word used to describe many forms of forgetting. It can impact both short- and long-term memory, encompassing abilities like name recall and even simple actions like brushing your teeth. It's normal to occasionally forget things, especially as you get older. An estimated 40% of those over 65 suffer from some form of age-related memory loss. But how can you determine whether there's a more serious issue at hand?Depending on how frequently and how much you forget things, you can decide if it's time to consider whether this is more than just normal ageing. This guide can assist you in distinguishing between memory lapses that are typical and those that require further investigation by a physician.
Track 20: Cognitive Rehabilitation:
The term "cognitive rehabilitation" describes a broad spectrum of research-based interventions intended to enhance cognitive functioning in people with brain injuries or other cognitive impairments in order to return them to normal or to make up for cognitive losses. It comprises a customised training and practice regimen for particular talents along with metacognitive techniques. One way to help the patient become more self-aware of their problem-solving abilities is to teach them how to assess their own performance and make required corrections. This is an example of a metacognitive strategy. It has been demonstrated that cognitive rehabilitation therapy, administered by a qualified therapist, is beneficial for people who have experienced a left or right hemisphere stroke. Cognitive rehabilitation therapy is a subset of cognitive rehabilitation, which is community-based rehabilitation, frequently in cases of traumatic brain injury, and supplied by rehabilitation professionals.
Benefits of Participants
1. Networking Opportunities:
- Connect with Experts: Engage with leading researchers, clinicians, and industry experts in Alzheimer's disease and dementia care.
- Collaborative Research: Explore potential collaborations for research projects and clinical trials with international peers.
2. Knowledge Enhancement:
- Cutting-Edge Research: Gain insights into the latest advancements in Alzheimer's research, including new treatment strategies, diagnostic tools, and care practices.
- Workshops & Seminars: Participate in interactive workshops and seminars that provide hands-on experience with the latest technologies and methodologies.
3. Professional Development:
- Continuing Education: Earn Continuing Medical Education (CME) credits or other professional development certifications.
- Skill Building: Enhance your expertise in diagnosing, treating, and managing Alzheimer's disease through specialized sessions.
4. Global Exposure:
- International Perspectives: Learn from global case studies and understand how Alzheimer's is addressed in different healthcare systems.
- Cultural Exchange: Experience a diverse array of perspectives and solutions from participants representing different countries and cultures.
5. Presentation Opportunities:
- Showcase Research: Present your own research findings to a global audience, receive feedback, and increase your visibility in the field.
- Poster Sessions: Participate in poster sessions to share your work and engage in in-depth discussions with attendees.
6. Innovation and Technology:
- Explore New Technologies: Discover the latest technological advancements in Alzheimer's care, including AI-driven diagnostics, therapeutic innovations, and care management tools.
- Industry Exhibits: Visit industry exhibitions to explore new products, services, and technologies that could enhance your practice or research.
7. Policy and Advocacy:
- Influence Policy: Engage in discussions with policymakers and advocates to influence the global agenda on Alzheimer’s care and research.
- Advocacy Training: Learn how to effectively advocate for better care policies and funding for Alzheimer's research in your own country.
8. Cultural Experience:
- Explore Paris: Enjoy the opportunity to explore Paris, a city rich in history, culture, and art, adding a memorable experience to your professional development.
- Social Events: Participate in social events that provide a relaxed environment to connect with fellow attendees while experiencing local culture.
9. Publication Opportunities:
- Publish Your Work: Selected abstracts and research papers may be published in leading journals or conference proceedings, providing wider recognition of your work.
10. Awards and Recognition:
- Awards for Excellence: Compete for awards recognizing outstanding contributions to the field of Alzheimer’s research and care, adding prestige to your professional profile.
Market Analysis
The 15th Global Alzheimer’s Summit scheduled for July 23-24, 2025, in Paris, France, we'll consider various aspects such as the significance of the event, the market landscape of Alzheimer's research and treatment, key trends, potential opportunities, and challenges.
- Networking Opportunity: It’s a critical opportunity for networking, forming partnerships, and collaboration between academia and the pharmaceutical industry.
- Educational Resource: Offers updates on clinical trials, drug development, care practices, and technological innovations
- Market Size and Growth: The global Alzheimer’s disease market was valued at approximately USD 6.2 billion in 2023, with a projected compound annual growth rate (CAGR) of 8.1% from 2023 to 2030.
- Key Players: Major pharmaceutical companies involved include Biogen, Eisai, Roche, Eli Lilly, Novartis, and Pfizer, among others. These companies are actively involved in drug development and research related to Alzheimer’s.
- R&D Focus: Significant focus on developing disease-modifying therapies (DMTs) and symptomatic treatments. Biomarker identification and early diagnosis are critical areas of research.
- Drug Pipeline: The drug pipeline is robust, with several disease-modifying drugs in various stages of clinical trials. Recent approvals, such as Aduhelm (aducanumab) by Biogen, have sparked both interest and controversy.
- Technological Integration: Increasing integration of AI and machine learning in diagnosis, treatment personalization, and patient monitoring.
- Dominance of Major Pharma: Large pharmaceutical companies dominate the Alzheimer’s treatment market, but smaller biotech firms are increasingly contributing innovative solutions.
- Patent Expirations: Upcoming patent expirations of existing drugs may lead to increased competition from generic manufacturers, affecting market dynamics.
- Innovation Showcase: The summit will likely showcase the latest innovations in Alzheimer’s research and treatment, influencing market trends and investment decisions.
To Collaborate Scientific Professionals around the World
Conference Date July 23-24, 2025
For Sponsors & Exhibitors
Speaker Opportunity
Useful Links
Past Conference Report
Supported By
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by